Spread | 0.10 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 5.05 |
Open | 4.92 |
1-Year Change | 65.1% |
Day's Range | 4.92 - 5.08 |
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicine. Its lead product candidates include SY-1425, SY-2101 and SY-5609. Its SY-1425, is a selective retinoic acid receptor alpha (RARα) that is being evaluated in combination with azacytidine used to treat acute myeloid leukemia (AML). Its SY-2101, a novel oral form of arsenic trioxide (ATO) being developed for the treatment of AML. Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors.
BRIEF: For the fiscal year ended 31 December 2021, Syros Pharmaceuticals Inc revenues increased 56% to $23.5M. Net loss increased 3% to $86.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development - Balancing value increase of 33% to $70M (expense), Labor & Related Expenses in R&D increase of 30% to $24.2M (expense).